Adipocytes in obesity: A perfect reservoir for SARS-CoV-2?
ACE2, angiotensin-converting enzyme 2
ATP, adenosine triphosphate
Adipocyte
COVID-19, coronavirus disease 2019
ER, endoplasmic reticulum
ERGIC, ER-to-Golgi intermediate compartment
FFAs, free fatty acids
LDs, lipid droplets
Lipid metabolism
Obesity
S protein, spike protein
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
Severe acute respiratory syndrome coronavirus 2
TAGs, triacylglycerols
Journal
Medical hypotheses
ISSN: 1532-2777
Titre abrégé: Med Hypotheses
Pays: United States
ID NLM: 7505668
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
07
07
2022
revised:
17
12
2022
accepted:
30
12
2022
entrez:
6
2
2023
pubmed:
7
2
2023
medline:
7
2
2023
Statut:
ppublish
Résumé
Research evidence suggests that adipocytes in obesity might facilitate SARS-CoV-2 replication, for it was only found in adipose tissue of individuals with overweight or obesity but not lean individuals who died from COVID-19. As lipid metabolism is key to adipocyte function, and viruses are capable of exploiting and manipulating lipid metabolism of host cells for their own benefit of infection, we hypothesize that adipocytes could not only impair host immune defense against viral infection, but also facilitate SARS-CoV-2 entry, replication and assembly as a reservoir to boost the viral infection in obesity. The latter of which could mainly be mediated by SARS-CoV-2 hijacking the abnormal lipid metabolism in the adipocytes. If these were to be confirmed, an approach to combat COVID-19 in people with obesity by taking advantage of the abnormal lipid metabolism in adipocytes might be considered, as well as modifying lipid metabolism of other host cells as a potential adjunctive treatment for COVID-19.
Identifiants
pubmed: 36742015
doi: 10.1016/j.mehy.2023.111020
pii: S0306-9877(23)00016-6
pmc: PMC9889082
doi:
Types de publication
Journal Article
Langues
eng
Pagination
111020Informations de copyright
© 2023 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Obes Med. 2020 Sep;19:100283
pubmed: 32835126
Thorax. 2013 Jul;68(7):684-6
pubmed: 23436045
Viruses. 2018 Mar 20;10(3):
pubmed: 29558400
Biochem J. 1990 Aug 1;269(3):807-14
pubmed: 2117922
Cell Res. 2007 Jun;17(6):486-511
pubmed: 17563755
Curr Opin Cell Biol. 2015 Aug;35:106-16
pubmed: 25988755
Obes Rev. 2001 May;2(2):131-40
pubmed: 12119664
Cytokine Growth Factor Rev. 2022 Feb;63:44-57
pubmed: 34836751
Mol Syst Biol. 2020 Jul;16(7):e9610
pubmed: 32715618
Int J Obes (Lond). 2013 Nov;37(11):1473-80
pubmed: 23478428
Curr Opin Virol. 2014 Dec;9:45-52
pubmed: 25262061
Front Cell Dev Biol. 2017 Dec 07;5:106
pubmed: 29270406
Diabetes. 2011 Oct;60(10):2441-9
pubmed: 21948998
J Cell Biol. 2021 Aug 2;220(8):
pubmed: 34165498
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Front Immunol. 2014 Oct 13;5:483
pubmed: 25352844
Dev Cell. 2017 Jun 19;41(6):591-604.e7
pubmed: 28579322
J Clin Invest. 2011 Jun;121(6):2094-101
pubmed: 21633177
Cell Rep. 2021 Aug 3;36(5):109479
pubmed: 34320401
Front Immunol. 2020 Nov 27;11:593058
pubmed: 33329579
Nat Rev Mol Cell Biol. 2019 Mar;20(3):137-155
pubmed: 30523332
Glob Health Action. 2020 Dec 31;13(1):1804700
pubmed: 32835634
Sci Rep. 2021 Mar 4;11(1):5207
pubmed: 33664446
Obesity (Silver Spring). 2020 Jul;28(7):1187-1190
pubmed: 32339391
Biochem J. 2020 Mar 13;477(5):985-1008
pubmed: 32168372
Cytokine Growth Factor Rev. 2004 Apr-Jun;15(2-3):103-10
pubmed: 15110794
Cell Metab. 2021 Nov 2;33(11):2174-2188.e5
pubmed: 34599884
J Cell Biol. 2015 Mar 2;208(5):501-12
pubmed: 25733711
Physiol Rev. 2010 Jan;90(1):207-58
pubmed: 20086077
Nat Rev Endocrinol. 2021 Mar;17(3):135-149
pubmed: 33479538
Int Rev Immunol. 2017 Mar 4;36(2):74-88
pubmed: 28333574
Cell Metab. 2022 Jan 4;34(1):1-2
pubmed: 34895500
Obesity (Silver Spring). 2008 Mar;16(3):700-5
pubmed: 18239555
PLoS Pathog. 2020 Dec 16;16(12):e1009127
pubmed: 33326472
Int J Clin Pharm. 2022 Jun;44(3):832-833
pubmed: 35449348
Nat Rev Endocrinol. 2021 May;17(5):276-295
pubmed: 33627836
Adv Exp Med Biol. 2017;960:135-160
pubmed: 28585198
Signal Transduct Target Ther. 2021 Jun 11;6(1):231
pubmed: 34117209
Eur J Clin Invest. 2018 Nov;48(11):e13017
pubmed: 30107041
Curr Opin Cell Biol. 2020 Oct;66:11-18
pubmed: 32416466
PLoS Biol. 2020 Jun 8;18(6):e3000715
pubmed: 32511245
Mol Cell Endocrinol. 2010 Apr 29;318(1-2):24-33
pubmed: 19720110
Cell Microbiol. 2014 Oct;16(10):1493-502
pubmed: 25131438
Endocrinology. 2008 Mar;149(3):942-9
pubmed: 18202123
Front Immunol. 2021 Apr 13;12:666693
pubmed: 33927728